BofA lowered the firm’s price target on Sarepta (SRPT) to $157 from $179 and keeps a Buy rating on the shares. The firm updated models in smid-cap biotech as part of a Q1 earnings preview.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta Therapeutics: Buy Rating Affirmed on Promising LGMD Program Progress and Regulatory Advancements
- Cautious Hold Rating on Sarepta Therapeutics Amid Limited LGMD Market and ELEVIDYS Uncertainties
- Sarepta Therapeutics’ Promising LGMD Pipeline and Regulatory Progress Support Buy Rating
- Sarepta announces pipeline progress for limb-girdle muscular dystrophy subtypes
- Walmart, Target initiated: Wall Street’s top analyst calls